Protein Folding Evidence Assurance
Review supplied protein-folding trajectory evidence with a deterministic research assessment before experimental interpretation.
Who this is for
- Protein science and structural-biology research teams.
- Computational biology groups reviewing folding trajectories.
- Research programs triaging folding and misfolding evidence.
The problem you already have
A single folding score can hide where the trajectory actually becomes inconsistent
The Part 38 disclosure treats protein folding as a causal trajectory rather than a single end-state score. For S02, that means the useful evidence is not only whether a case looks “good” or “bad”, but whether the supplied sequence of folding states remains coherent or develops a localized obstruction that deserves review.
Misfolding evidence and late aggregation evidence are not the same thing
Part 38 separates folding-pathway obstruction from the later amyloid-topology gate. That distinction helps a research team avoid collapsing early trajectory instability and later aggregation-related evidence into one label when the supplied case only supports one of those conclusions.
Computational folding evidence must remain separate from experimental structure determination
The current S02 capability is functional and research-only, while Part 38 itself requires experimental and clinical validation. The assessment therefore provides a bounded research classification and evidence record, not an experimentally validated structure, binder assay or clinical conclusion.
Real-World Operational Scenario: The Trajectory That Looked Acceptable Until One Folding Stage Broke the Pattern
Scenario: Most frames in a folding trajectory appear directionally consistent, but one transition behaves differently enough to change the interpretation.
A structural-biology team is comparing two candidate trajectories before deciding which one deserves deeper simulation or experimental work.
WITHOUT this gate: The overall score can make both trajectories look similar, and a localized obstruction can be diluted by the rest of the sequence.
WITH this gate: The supplied frames remain in sequence, the obstruction evidence stays attached to the specific transition, and the team receives a bounded research classification showing which trajectory is more internally coherent without claiming experimental structural proof.
What BivectorAI Provides
Trajectory-Level Folding Evidence
Reviews the supplied folding frames as an ordered research trajectory so state-to-state consistency remains visible instead of being reduced to one aggregate score.
Misfolding Obstruction Review
Preserves whether a supplied trajectory contains an obstruction-like transition that should be separated from otherwise coherent folding evidence.
Aggregation Evidence Separation
Keeps later amyloid-related evidence conceptually distinct from earlier folding-pathway instability so one mechanism is not used to overstate another.
Research-Only Validation Boundary
Outputs remain deterministic computational research evidence for scientific review and do not constitute experimentally validated protein structures, binding results or clinical evidence.
Prove the Gate Before Broader Integration
Back-test the folding gate against frozen trajectories with known expert or experimental disposition.
Freeze the accepted frame format, trajectory ordering, obstruction criteria, classification labels and acceptance boundary before revealing the reference disposition. Broader integration is justified only if the same contract reproducibly separates coherent from obstruction-bearing trajectories while keeping experimental validation outside the computational claim.
What you provide
A bounded set of protein-folding frames or trajectory-derived evidence in the agreed research format.
What BivectorAI actually hands you
Folding-evidence classification
A bounded research classification tied directly to the submitted frames or trajectory-derived evidence.
Pathway-obstruction finding
An explicit indication of whether the supplied trajectory contains a folding-pathway inconsistency that warrants deeper scientific review.
Input-linked evidence certificate
A deterministic record tying the returned classification and obstruction finding to the exact bounded evidence package.
Human-owned follow-up boundary
A review record that states what remains computational, what requires experimental validation and which next scientific decisions remain with your team.
What we will never ask you for
Protein research often sits inside a much larger proprietary biology program. The assessment is limited to the bounded folding evidence needed for the agreed research question, while patient information, clinical authority and unsupported experimental-validation claims stay outside scope.
- Clinical decision authority.
- Patient information.
- A claim that computational folding evidence is experimentally validated.
- Unnecessary proprietary biology data outside the evaluation scope.
How it actually runs
Start with a bounded evaluation, not a large commitment
Fixed scope / quoted per engagement. Evidence boundary, inputs, outputs and acceptance criteria are agreed before work begins.
We do not open with an annual license. If the bounded protein-folding review does not establish that the research evidence is useful for the agreed folding question, there is no reason to move into a broader commercial commitment.
Bounded evidence contract, private integration and agreed evaluation scope.
Annual access only within an agreed and evidence-supported capability boundary.
Fixed program scope where a bounded research or evidence campaign is preferred.
Current capability is a functional research-only protein-folding assessment. It is not a medical device, clinical advice, an experimentally validated protein-structure determination, binder-validation assay or clinical evidence.